Targeting the vitamin D receptor: advances in drug discovery

Bibliography

• MANGELSDORF DJ, THUMMEL C, BEATO M et al.: The nuclear receptor superfamily: the second decade. Cell (1995) 83:835–839.
   PubMed Web of Science ®Google Scholar
• •Excellent review on the molecular biology of nuclear receptors.
   Google Scholar
• MAKISHIMA M: Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors. J. PharmacoL Sci. (2005) 97:177–183.
   PubMed Web of Science ®Google Scholar
• GLASS CK, ROSENFELD MG: The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. (2000) 14:121–141.
   PubMed Web of Science ®Google Scholar
• •Excellent review on nuclear receptor cofactors.
   Google Scholar
• HAUSSLER MR, WHITFIELD GK, HAUSSLER CA et al.: The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner. Res. (1998) 13:325–349.
   PubMed Web of Science ®Google Scholar
• ••Excellent review on VDR biology.
   Google Scholar
• SHULMAN M, LARSON C, MANGELSDORF DJ, RANGANATHAN R: Structural determinants of allosteric ligand activation in RXR heterodimers. Cell (2004) 116:417–429.
   PubMed Web of Science ®Google Scholar
• MALLOY PJ, PIKE JW, FELDMAN D: The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocrine Rev. (1999) 20:156–188.
   PubMedGoogle Scholar
• •Excellent review on HVDRR.
   Google Scholar
• YOSHIZAWA T, HANDA Y, UEMATSU Yet al.: Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet. (1997) 16:391–396.
   Google Scholar
• •The first report describing VDR knockout mice.
   Google Scholar
• ROCHEL N, WURTZ JM, MITSCHLER A. KLAHOLZ B, MORAS D: The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. MoL Cell (2000) 5:173–179.
   Google Scholar
• ROCHEL N, TOCCHINI- VALENTINI G, EGEA PF et al.: Functional and structural characterization of the insertion region in the ligand binding domain of the vitamin D nuclear receptor. Eur. j Biochem. (2001) 268:971–979.
   PubMedGoogle Scholar
• TOCCHINI-VALENTINI G, ROCHEL N, WURTZ JM, MORAS D: Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification. J. Med. Chem. (2004) 47:1956–1961.
   Google Scholar
• VANHOOKE JL, BENNING MM, BAUER CB, PIKE JW, DELUCA HF: Molecular structure of the rat vitamin D receptor ligand binding domain complexed with 2-carbon-substituted vitamin D, hormone analogues and a LXXLL-containing co-activator peptide. Biochemistry (2004) 43:4101–4110.
   PubMed Web of Science ®Google Scholar
• LI YC, AMLING M, PIRRO AE et aL: Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia but not alopecia in vitamin D receptor-ablated mice. Endocrinology (1998) 139:4391–4396.
   PubMed Web of Science ®Google Scholar
• VAN CROMPHAUT SJ, DEWERCHIN M, HOENDEROP JGJ et al.: Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc. Natl. Acad. Sci. USA. (2001) 98:13324–13329.
   PubMed Web of Science ®Google Scholar
• NORMAN AW, OKAMURA WH, HAMMOND MW et al.: Comparison of 6-s-cis- and 6-s-trans-locked analogs of la,25-dihydroxyvitamin D, indicates that the 6-s-cis conformation is preferred for rapid nongenomic biological responses and that neither 6-s-cis- nor 6-s-trans-locked analogs are preferred for genomic biological responses. MoL EndocrinoL (1997) 11:1518–1531.
   PubMedGoogle Scholar
• KITAZAWA R, KITAZAWA S: Vitamin D3 augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. Biochem. Biophys. Res. Commun. (2002) 290:650–655.
   PubMedGoogle Scholar
• TANAKA H, SEINO Y: Direct action of 1,25-dihydroxyvitamin D on bone: VDRKO bone shows excessive bone formation in normal mineral condition. J. Steroid Biochem. MoL Biol. (2004) 89–90:343–345.
   Google Scholar
• YASUDA H, SHIMA N, NAKAGAWA N et aL: Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. NatL Acad. Sci. USA (1998) 95:3597–3602.
   PubMed Web of Science ®Google Scholar
• SHEVDE NK, PLUM LA, CLAGETT-DAME M, YAIVIAMOTO H, PIKE JW, DELUCA HF: A potent analog of la,25-dihydroxyvitamin D3 selectively induces bone formation. Proc. Natl. Acad. Sci. USA (2002) 99:13487–13491.
   PubMedGoogle Scholar
• ZANELLO LP, NORMAN AW: Rapid modulation of osteoblast ion channel responses by la,25(OH)2-vitamin D3 requires the presence of a functional vitamin D nuclear receptor. Proc. NatL Acad. Sci. USA (2004) 101:1589–1594.
   PubMedGoogle Scholar
• RICHY F, ETHGEN 0, BRUYERE 0, REGINSTER JY: Efficacy of a-calcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int. (2004) 15:301–310.
   PubMed Web of Science ®Google Scholar
• BLAND R: Steroid hormone receptor expression and action in bone. Clin. (2000) 98:217–240.
   Google Scholar
• NAGPAL S, NA S, RATHNACHALAM R: Non-calcemic actions of vitamin D receptor ligands. Endocr. Rev. (2005) 26:662–687.
   PubMed Web of Science ®Google Scholar
• ••Excellent recent review of VDR biology.
   Google Scholar
• KURIHARA N, ISHIZUKA S, DEMULDER A, MENAA C, ROODMAN GD: Paget's disease - A VDR co-activator disease? J. Steroid Biochem. MoL Biol. (2004) 89–90:321-325. Excellent review on the role of VDR in Paget's disease.
   Google Scholar
• ROODMAN GD, WINDLE JJ: Paget disease of bone. J. Clin. Invest. (2005) 115:200–208.
   PubMed Web of Science ®Google Scholar
• •Excellent review of Paget's disease.
   Google Scholar
• ISHIZUKA S, KURIHARA N, MIURA D et aL: Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by la,25-dihydroxyvitamin D3 from pagetic bone marrow cells. J. Steroid Biochem. MoL Biol. (2004) 89–90:331–334.
   Google Scholar
• SAKAI Y, DEMAY MB: Evaluation of keratinocyte proliferation and differentiation in vitamin D receptor knockout mice. Endocrinology (2000) 141:2043–2049.
   PubMed Web of Science ®Google Scholar
• SAKAI Y, KISHIMOTO J, DEMAY MB: Metabolic and cellular analysis of alopecia in vitamin D receptor knockout mice. Clin. Invest. (2001) 107:961–966.
   Google Scholar
• MILLER J, DJABALI K, CHEN T et al.:Atrichia caused by mutations in the vitamin D receptor gene is a phenocopy of generalized atrichia caused by mutations in the hairless gene. J. Invest. DermatoL (2001) 117:612–617.
   PubMed Web of Science ®Google Scholar
• HSIEH JC, SISK JM, JURUTKA PW et al.: Physical and functional interaction between the vitamin D receptor and hairless corepressor, two proteins required for hair cycling. J. Biol. Chem. (2003) 278:38665–38674.
   PubMedGoogle Scholar
• SKORIJA K, COX M, SISK JM et aL: Ligand-independent actions of the vitamin D receptor maintain hair follicle homeostasis. Mol Endocrina (2005) 19:855–862.
   PubMed Web of Science ®Google Scholar
• KANG S, YT S, GRIFFITHS CE, FANCHER L, HAMILTON TA, CHOI JH: Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br. J. Dermatol (1998) 138:77–83.
   PubMed Web of Science ®Google Scholar
• ADORINI L, PENNA G, GIARRATANA N et al.: Dendritic cells as key targets for immunomodulation by vitamin D receptor ligands. J. Steroid Biochem. Mol. Biol. (2004) 89–90:437–441.
   Google Scholar
• MAKISHIMA M, LU TT, XIE W et al.: Vitamin D receptor as an intestinal bile acid sensor. Science (2002) 296:1313–1316.
   PubMed Web of Science ®Google Scholar
• RUSSELL DW: The enzymes, regulation, and genetics of bile acid synthesis. Ann. Rev. Biochem. (2003) 72:137–174.
   PubMed Web of Science ®Google Scholar
• NAGENGAST FM, GRUBBEN MJ, VAN MUNSTER IP: Role of bile acids in colorectal carcinogenesis. Eur. J. Cancer (1995) 31A :1067–1070.
   PubMed Web of Science ®Google Scholar
• STAUDINGER JL, GOODWIN B, JONES SA et al.: The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl Acad. Sci. USA (2001) 98:3369–3374.
   PubMed Web of Science ®Google Scholar
• XIE W, RADOMINSKA-PANDYA A, SHI Yet al.: An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl Acad. Sci. USA (2001) 98:3375–3380.
   Google Scholar
• ADACHI R, SHULMAN Al, YAMAMOTO K et al.: Structural determinants for vitamin D receptor response to endocrine and xenobiotic signals. Mol. EndocrinoL (2004) 18:43–52.
   Google Scholar
• ECHCHGADDA I, SONG CS, ROY AK, CHAUERJEE B: Dehydroepiarulrosteronesulfotransferase is a target for transcriptional induction by the vitamin D receptor. Mol Pharmacol (2004) 65:720–729.
   PubMed Web of Science ®Google Scholar
• MCCARTHY TC, LI X, SINAL CJ: Vitamin D receptor-dependent regulation of colon multi-drug resistance-associated protein-3 gene expression by bile acids. J. Biol. Chem. (2005) 280:23232–23242.
   PubMed Web of Science ®Google Scholar
• BOUILLON R, OKAMURA WH, NORMAN AW: Structure-function relationships in the vitamin D endocrine system. Endocr. Rev. (1995)16:200–257.
   PubMed Web of Science ®Google Scholar
• ••Excellent recent review of VDR analoguesin cancer therapy.
   Google Scholar
• GARLAND CF, GARLAND FC, GORHAM ED: Calcium and vitamin D. Their potential roles in colon and breast cancer prevention. Ann. IVY Acad. Sci. (1999) 889:107–119.
   PubMed Web of Science ®Google Scholar
• MIYAURA C, ABE E, KURIBAYASHI T et al.: la,25-Dihydroxyvitamin D, induces differentiation of human myeloid leukaemia cells. Biochem. Biophys. Res. Commun. (1981) 102:937–943.
   PubMed Web of Science ®Google Scholar
• HONMA Y, HOZUMI M, ABE E et al.: la,25-Dihydroxyvitamin D, and 1a-hydroxyvitamin D3 prolong survival time of mice inoculated with myeloid leukaemia cells. Proc. Natl Acad. Sci. USA (1983) 80:201–204.
   PubMed Web of Science ®Google Scholar
• VERLINDEN L, VERSTUYF A, CONVENTS R, MARCELIS S, VAN CAMP M, BOUILLON R: Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol. Cell. Endocrinol. (1998)142:57–65.
   PubMed Web of Science ®Google Scholar
• LIU M, LEE MH, COHEN M, BOMMAKANTI M, FREEDMAN LP: Transcriptional activation of the CDK inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. (1996)10:142–153.
   PubMed Web of Science ®Google Scholar
• INOUE T, KAMIYAMA J, SAKAI T: Spl and NF-Y synergistically mediate the effect of vitamin D3 in the p27',1 gene promoter that lacks vitamin D response elements. J. Biol Chem. (1999) 274:32309–32317.
   PubMedGoogle Scholar
• ROTS NY, LIU M, ANDERSON EC, FREEDMAN LP: A differential screen for ligand-regulated genes: identification of Hoth10 as a target of vitamin D3 induction in myeloid leukemic cells. Mol. Cell. Biol. (1998)18:1911–1918.
   PubMedGoogle Scholar
• EELEN G, VERLINDEN L, VAN CAMP M et al.: The effects of la,25-dihydroxyvitamin D3 on the expression of DNA replication genes. J. Bone Miner. Res. (2004) 19:133–146.
   Google Scholar
• MAKISHIMA M, SHUDO K, HONMAY: Greater synergism of retinoic acid receptor (RAR) agonists with vitamin D3 than that of retinoid X receptor (RXR) agonists with regard to growth inhibition and differentiation induction in monoblastic leukaemia cells. Biochem. Pharmacol. (1999)57:521–529.
   PubMedGoogle Scholar
• MAKISHIMA M, OKABE-KADO J, HONMA Y: Growth inhibition and differentiation induction in human monoblastic leukaemia cells by 1a-hydroxyvitamin D derivatives and their enhancement by combination with hydroxyurea. Br. J. Cancer (1998) 77:33–39.
   PubMedGoogle Scholar
• DANILENKO M, WANG Q, WANG X, LEVY J, SHARONI Y, STUDZINSKI GP: Carnosic acid potentiates the antioxidant and prodifferentiation effects of la,25-dihydroxyvitamin D3 in leukaemia cells but does not promote elevation of basal levels of intracellular calcium. Cancer Res. (2003) 63:1325–1332.
   PubMed Web of Science ®Google Scholar
• GUYTON KZ, KENSLER TW, POSNER GH: Vitamin D and vitamin D analogs as cancer chemopreventive agents. Nutr. Rev. (2003) 61:227–238.
   PubMed Web of Science ®Google Scholar
• •Excellent review of vitamin D in cancer prevention.
   Google Scholar
• ADACHI R, HONMA Y, MASUNO H et al.: Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative. J. Lipid Res. (2005) 46:46–57.
   PubMed Web of Science ®Google Scholar
• MATHIEU C, VAN ETTEN E, DECALLONNE B et al.: Vitamin D and 1,25-dihydroxyvitamin D3 as modulators in the immune system. J. Steroid Biochem. Mol. Biol. (2004) 89–90:449–452.
   Google Scholar
• •Excellent review of the role of VDR in Type 1 diabetes.
   Google Scholar
• GRIFFIN MD, LUTZ W, PHAN VA, BACHMAN LA, MCKEAN DJ, KUMAR R: Dendritic cell modulation by la,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl Acad. Sci. USA. (2001) 98:6800–6805.
   PubMed Web of Science ®Google Scholar
• BOONSTRA A, BARRAT FJ, CRAIN C,HEATH VL, SAVELKOUL HFJ, O'GARRA A: la,25-Dihydroxyvitamin D3 has a direct effect on naive CD4* T cells to enhance the development of TH2 cells. Immunol (2001) 167:4974–4980.
   Google Scholar
• CANTORNA MT, HAYES CE, DELUCA HF: 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc. Natl. Acad. Sci. USA (1996) 93:7861–7864.
   PubMed Web of Science ®Google Scholar
• CANTORNA MT, WOODWARD WD, HAYES CE, DELUCA HF: 1,25-Dihydroxyvitamin D, is a positive regulator for the two antiencephalitogenic cytokines TGF-01 and IL-4. J. Immunol. (1998) 160:5314–5319.
   PubMed Web of Science ®Google Scholar
• CANTORNA MT, HAYES CE, DELUCA HF: 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J. Nutr. (1998) 128:68–72.
   PubMed Web of Science ®Google Scholar
• ANDJELKOVIC Z, VOJINOVIC J, PEJNOVIC Net al.: Disease modifying and immunomodulatory effects of high dose la(OH)D3 in rheumatoid arthritis patients. Clin. Exp. Rheumatol. (1999) 17:453–456.
   Google Scholar
• MATHIEU C, GYSEMANS C, GIULIETTI A. BOUILLON R: Vitamin D and diabetes. Diabetologia (2005) 48:1247–1257.
   PubMed Web of Science ®Google Scholar
• •Excellent review of the role of VDR in diabetes.
   Google Scholar
• MATHIEU C, WAER M, LAUREYS J, RUTGEERTS 0, BOUILLON R: Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia (1994) 37:552–558.
   PubMed Web of Science ®Google Scholar
• MATHIEU C, WAER M, CASTEELS K, LAUREYS J, BOUILLON R: Prevention of Type 1 diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060. Endocrinology (1995) 136:866–872.
   PubMed Web of Science ®Google Scholar
• OVERBERGH L, DECALLONNE B, WAER M et al.: la,25-dihydroxyvitamin D3 induces an autoantigen-specific TH / TH2 immune shift in NOD mice immunized with GAD65 (p524-543). Diabetes (2000) 49:1301–1307.
   PubMed Web of Science ®Google Scholar
• MATHIEU C, VAN ETTEN E, GYSEMANS Get aL: In vitro and in vivo analysis of the immune system of vitamin D receptor knockout mice. J. Bone Miner. Res. (2001) 16:2057–2065.
   PubMed Web of Science ®Google Scholar
• VAN ETTEN E, DECALLONNE B, VERLINDEN L, VERSTUYF A. BOUILLON R, MATHIEU C: Analogs of la,25-chhydroxyvitamin D3 as pluripotent immunomodulators. J. Cell. Biochem. (2003) 88:223–226.
   PubMed Web of Science ®Google Scholar
• LI YC, KONG J, WEI M, CHEN ZF, LIU SQ, GAO LP: 1,25-dihyrdoxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. (2002) 110:155–156.
   PubMedGoogle Scholar
• GOODMAN WG, RAMIREZ JA, BELIN TR et al.: Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int. (1994) 46:1160–1166.
   PubMed Web of Science ®Google Scholar
• GOODMAN WG, GOLDIN J, KUIZON BD et al.: Coronary-artery calcification in young adults with end stage renal disease who are undergoing dialysis. N Engl. J. Med. (2000) 342:1478–1483.
   PubMed Web of Science ®Google Scholar
• TENG M, WOLF M, LOWRIE E, OFSTHUN N, LAZARUS JM, THADHANI R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl. J. Med. (2003) 349:446–456.
   PubMed Web of Science ®Google Scholar
• SATO H, SUGIMOTO I, MATSUNAGAT et al.: Tacalcitol (1,24(OH)203, TV-02) inhibits phorbol ester-induced epidermal proliferation and cutaneous inflammation, and induces epidermal differentiation in mice. Arch. DermatoL Res. (1996) 288:656–663.
   PubMedGoogle Scholar
• VERLINDEN L, VERSTUYF A, QUACK M et al.: Interaction of two novel 14-epivitamin D3 analogs with vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D3 responsive elements. J. Bone Miner. Res. (2001) 16:625–638.
   Google Scholar
• PERAKYLA M, MALINEN M, HERZIG KH, CARLBERG C: Gene regulatory potential of nonsteroidal vitamin D receptor ligands. MoL Endocrinol. (2005) 19:2060–2073.
   PubMedGoogle Scholar
• YAMADA S, SHIMIZU M, YAMAMOTO K: Structure-function relationships of vitamin D including ligand recognition by the vitamin D receptor. Med. Res. Rev. (2003) 23:89–115.
   PubMedGoogle Scholar
• •Excellent review of the structure-function relationship between vitamin D analogues and VDR.
   Google Scholar
• CHOI M, YAMAMOTO K, ITOH T et al.: Interaction between vitamin D receptor and vitamin D ligands: two-dimensional alanine scanning mutational analysis. Chem. Biol. (2003) 10:261–270.
   PubMedGoogle Scholar
• KITAGAWA H, FUJIKI R, YOSHIMURA K et al.: The chromatin-remodeling complex WINAC targets a nuclear receptor to promoters and is impaired in Williams syndrome. Cell (2003) 113:905–917.
   PubMed Web of Science ®Google Scholar
• HUHTAKANGAS JA, OLIVERA CJ, BISHOP JE, ZANELLO LP, NORMAN AW: The vitamin D receptor is present in caveolae-enriched plasma membranes and binds la,25(OH)2-Vitamin D3 in vivo and in vitro. MoL Endocrinol. (2004) 18:2660–2671.
   PubMed Web of Science ®Google Scholar
• VERTINO AM, BULA CM, CHEN JR et al.: Nongenotropic, antiapoptotic signalling of la,25(OH)2-vitamin D3 and analogs through the ligand binding domain of the vitamin D receptor in osteoblasts and osteocytes: mediation by Src, phosphatidylinositol 3-, and JNK kinases. J Biol. Chem. (2005) 280:14130–14137.
   PubMed Web of Science ®Google Scholar